Physician profile
Michael Gambla
NPI 1952367641
$27,314.38
in general payments reported to CMS, 2019-2025
47 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,695 · 2020: $5,994 · 2021: $9,530 · 2022: $1,097 · 2023: $1,332 · 2024: $1,243 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17,067.32 | 2019-2021 | |
| Astellas Pharma US INC | $1,486.47 | 2019-2024 | Myrbetriq |
| Progenics Pharmaceuticals, INC. | $1,385.80 | 2020-2023 | Pylarify |
| Boston Scientific Corporation | $1,082.14 | 2019-2025 | Lumenis Pulse 120h, Lithovue, Ams 700 |
| Olympus America INC. | $757.37 | 2023-2025 | Itind System, Soltive |
| Myriad Genetic Laboratories, INC. | $656.27 | 2021-2025 | Prolaris, Myrisk |
| Sumitomo Pharma America, INC. | $607.55 | 2023-2025 | Orgovyx, Gemtesa |
| Neotract INC. | $458.85 | 2019 | |
| Coloplast Corp | $380.58 | 2019-2025 | Stenostent, Speedicath |
| Urogen Pharma, INC. | $375.79 | 2022-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $311.67 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $222.87 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.33 | 2019-2025 | |
| Procept Biorobotics Corporation | $207.74 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Pfizer INC. | $177.19 | 2019-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $158.89 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Urovant Sciences INC | $158.15 | 2021-2022 | |
| 180 Medical, INC. | $124.74 | 2021-2025 | |
| Lumenis, INC | $119.62 | 2021 | |
| Axonics, INC. | $108.45 | 2020-2022 | |
| Tolmar, INC. | $104.95 | 2023-2025 | Eligard |
| Tolmar Pharmaceuticals, INC. | $104.27 | 2019-2022 | |
| Myovant Sciences INC. | $95.00 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $94.74 | 2019-2021 | |
| Blue Earth Diagnostics | $90.39 | 2019-2022 | |
| Amgen INC. | $77.57 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $72.39 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Medtronic, INC. | $69.05 | 2021-2025 | Interstim |
| Abbvie INC. | $65.84 | 2024 | |
| Janssen Biotech, INC. | $64.48 | 2019-2023 | Erleada |
| Convatec INC. | $58.07 | 2021-2023 | |
| C. R. Bard, INC. & Subsidiaries | $50.20 | 2024-2025 | Bard Urinary Drainage Bag |
| Civco Medical Instruments | $39.20 | 2024-2025 | |
| Teleflex LLC | $34.46 | 2021 | |
| Becton, Dickinson and Company | $27.10 | 2025 | Bard Urinary Drainage Bag |
| Calyxo, INC. | $23.31 | 2025 | Cvac Aspiration System |
| Palette Life Sciences, INC. | $23.12 | 2022 | |
| Halozyme INC | $21.82 | 2023 | |
| Bluewind Medical | $21.29 | 2025 | Revi |
| Karl Storz Endoscopy-America | $19.63 | 2024 | Hopkins |
| Rochester Medical Corporation | $17.14 | 2022 | |
| Coopersurgical, INC. | $16.70 | 2021 | |
| Koelis INC. | $15.71 | 2023 | |
| Abc Home Medical Supply, INC. | $15.17 | 2022 | |
| Merck Sharp & Dohme LLC | $14.82 | 2023 | Bridion |
| Cook Medical LLC | $14.17 | 2023 | Resonance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,109.49 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gambla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.